Unigene will establish a joint venture in China with Shijiazhuang Pharma that will use a biologic process to produce Fortical, a nasal spray formulation of calcitonin salmon indicated for osteoporosis. Currently, Unigen employs chemical synthesis to manufacture the drug. According to Shijiazhuang Pharma, the biologic process, using genetic fermentation technology, is much more efficient. Unigene and Sjihiazhuang will each invest $15 million in the JV. More details...

Stock Symbols: (OTCBB: UGNE) (NYSE: GSK) (NYSE: NVS)